# OnCo record paper-turner-serena-6-extended-lancet-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-turner-serena-6-extended-lancet-oncol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-turner-serena-6-extended-lancet-oncol-2026" ;
  schema:name "Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial"@en ;
  schema:description "With longer follow-up, switching to camizestrant when an ESR1 mutation appeared in the blood kept its benefit and also lengthened control on the next treatment."@en ;
  schema:url <https://onco.cc/key-papers/paper-turner-serena-6-extended-lancet-oncol-2026/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(26)00287-1>, <https://pubmed.ncbi.nlm.nih.gov/42442380/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(26)00287-1> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Turner NC, Mayer EL, Park YH, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/guardant360-cdx/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/serena-6/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .